Pharma News: Conflicts, Court Cases & Updates
- The Trump administration is pressuring pharmaceutical companies to negotiate drug prices to match those of other countries, which are typically lower than in the united States.
- This proclamation follows statements from pharmaceutical executives anticipating further details regarding which drugs would be subject to negotiations and their target prices.
- In related news, two new vaccine advisers appointed by HHS Secretary Robert F.
The Trump governance is shaking up the pharmaceutical landscape, demanding drug price negotiations with pharma companies and setting the stage for perhaps lower costs. This aggressive stance on drug prices aims to make U.S.costs comparable to those in other developed nations and will be a welcome change for many Americans. Simultaneously occurring, Health and Human Services appointed vaccine advisers with past ties to Merck lawsuits—a growth sure to stir controversy. Get the full story at News Directory 3, where you can stay informed of the legal battles and see how these conflicts might impact the industry. Discover what’s next for pharma and the potential implications to consumers.
Trump Administration Urges Drug Price Negotiations for Fair Pricing
Updated June 13, 2025
The Trump administration is pressuring pharmaceutical companies to negotiate drug prices to match those of other countries, which are typically lower than in the united States. A Health and Human Services (HHS) spokesperson stated that the administration is demanding pharmaceutical companies engage in clear pricing negotiations to lower drug prices for Americans. The spokesperson did not specify how the companies were allegedly obstructing progress.
This proclamation follows statements from pharmaceutical executives anticipating further details regarding which drugs would be subject to negotiations and their target prices. The push for pharmaceutical price negotiations aims to bring U.S. drug costs in line with those of other economically comparable nations.
In related news, two new vaccine advisers appointed by HHS Secretary Robert F. Kennedy Jr. have previously served as paid expert witnesses for plaintiffs suing Merck over its vaccines for measles, mumps, and cancer, according to Bloomberg News. robert Malone, a scientist who has promoted debunked vaccine safety theories, and Martin Kulldorff, a Harvard-trained epidemiologist who has studied vaccine side effects, have joined the U.S. Centers for disease Control and Prevention committee on immunization policy.
Court filings reveal that both Malone and Kulldorff have been compensated by attorneys representing plaintiffs in cases against Merck.Kulldorff earned thousands of dollars as an expert witness for plaintiffs alleging Merck concealed risks associated with its Gardasil vaccine, which targets cancers linked to human papillomavirus. The first jury trial related to these Gardasil claims is scheduled for September in Los Angeles. Malone was paid $350 per hour to prepare a report for plaintiffs in antitrust litigation accusing Merck of misleading regulators about the effectiveness of its vaccines for mumps, measles, and rubella to protect its market share.
What’s next
The pharmaceutical industry’s response to the administration’s demands and the outcomes of the Gardasil lawsuits will be closely watched in the coming months.